Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Naval Daver, Naveen Pemmaraju, Mikkael A. Sekeres, Amir T. Fathi, Andrew A. Lane, Anna Compagnoni, Ira Gupta, Alessandra Tosolini, Jessica Garzon, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 4265.1.

https://doi.org/10.1182/blood-2024-193593

Published: 2024

Journal Articles

Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

Marina Konopleva, Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, David A. Rizzieri, Eunice S. Wang, Sumithira Vasu, Todd Rosenblat, Michael Zuurman, Ira Gupta, Andrew A. Lane

Blood (2024) 144 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2024-200230

Published: 2024

Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Blood (2022) 140 (Supplement 1): 7301–7303.

https://doi.org/10.1182/blood-2022-164877

Published: 2022

Journal Articles

DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, Aránzazu Alonso Alonso, Hang Quach, Youngil Koh, Andreas Guenther, Chang-Ki Min, Xiaoou L. Zhou, Morrys Kaisermann, Lukasz M. Mis, Danaè Williams, Anne Yeakey, Geraldine Ferron-Brady, David J. Figueroa, Brandon E. Kremer, Ira Gupta, Wojciech Janowski

Blood (2021) 138 (Supplement 1): 2738.

https://doi.org/10.1182/blood-2021-153315

Published: 2021

Journal Articles

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Rakesh Popat, Aikaterini Kazantzi, MD, Asim Farooq, MD, Praneetha Thulasi, MD, Sagar Lonial, MD FACP, Andrzej Jakubowiak, MD PhD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Joanna Opalinska, MD, January Baron, MS, Trisha Piontek, BSN, Julie Byrne, PhD, Lynsey Womersley, MSc, Ira Gupta, MD, Simona Degli Esposti, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-139315

Published: 2020

Journal Articles

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sagar Lonial, MD FACP, Peter M. Voorhees, MD, Simona Degli Esposti, MD, Ira Gupta, MD, Joanna Opalinska, MD, Sandhya Sapra, PhD, Boris Gorsh, PharmD, Zangdong He, PhD, David M Kleinman, MD, Debra Schaumberg, OD, MPH, ScD, Angely Loubert, PharmD, MSc, Juliette Meunier, MSc, Antoine Regnault, PhD, Laurie Eliason, MPH

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-140013

Published: 2020

Journal Articles

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, MD, Randy Davis, PhD, Nicole M. Lewis, MSc, Kalpana K. Bakshi, MSc, Bikramjit Chopra, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Laurie Eliason, MPH, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Frank S. Wu, MDPhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-139785

Published: 2020

Journal Articles

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139182

Published: 2020

Journal Articles

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-139181

Published: 2020

Journal Articles

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ajay Nooka, MDMPH, Hans C. Lee, MD, Ashraf Z. Badros, MD, Peter Voorhees, MD, Malin Hultcrantz, MD PhD, Lionel Karlin, MD, Bertrand Arnulf, MD, Paul G. Richardson, MD, Eric Zhi, PhD, January Baron, MS, Trisha Piontek, BSN, Eric Lewis, MD, Joanna Opalinska, MD PhD, Ira Gupta, MD, Adam D. Cohen, MD, Sagar Lonial, MD FACP

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-139687

Published: 2020

Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139332

Published: 2020

Journal Articles

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sagar Lonial, MD FACP, Ajay Nooka, MDMPH, Praneetha Thulasi, MD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Natalie S. Callander, MD, Douglas Sborov, MD MS, Brian E. Zaugg, MD, Rakesh Popat, Simona Degli Esposti, MD, Julie Byrne, PhD, Joanna Opalinska, MD PhD, January Baron, MS, Trisha Piontek, BSN, Ira Gupta, MD, Reza Dana, MD MSc, MPH, Asim Farooq, MD, Andrzej Jakubowiak, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140078

Published: 2020

Journal Articles

Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines

Stephen Eastman, BS, MS, Christopher Shelton, Ira Gupta, Julie Krueger, Christina Blackwell, Paul M Bojczuk

Blood (2019) 134 (Supplement_1): 4401.

https://doi.org/10.1182/blood-2019-123705

Published: 2019

Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska

Blood (2019) 134 (Supplement_1): 1857.

https://doi.org/10.1182/blood-2019-129879

Published: 2019

Journal Articles

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Blood (2019) 133 (7): 676–687.

https://doi.org/10.1182/blood-2018-08-869008

Published: 2019

Includes: Supplemental data

Journal Articles

Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2 ) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time

Eytan M. Stein, MD, Richard M. Stone, MD, Daniel A. Pollyea, MD, Gail J. Roboz, MD, Jessica K. Altman, MD, Courtney D. DiNardo, MDMSc, Stephane de Botton, MD PhD, Nora Tu, PhD, Arlene S. Swern, PhD, Alessandra Tosolini, BS, Ira Gupta, MD, Samuel V. Agresta, MD, Amir T. Fathi, MD MD BS

Blood (2017) 130 (Supplement 1): 1299.

https://doi.org/10.1182/blood.V130.Suppl_1.1299.1299

Published: 2017

Journal Articles

Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML)

Daniel A. Pollyea, MD, Martin S. Tallman, MD, Stephane De Botton, Courtney D. DiNardo, MDMSc, Hagop M. Kantarjian, MD, Robert H. Collins, MD, Anthony S. Stein, MD, Qiang Xu, PhD, Alessandra Tosolini, BS, Ira Gupta, MD, Samuel V. Agresta, MD, Eytan M. Stein, MD

Blood (2017) 130 (Supplement 1): 638.

https://doi.org/10.1182/blood.V130.Suppl_1.638.638

Published: 2017

Journal Articles

Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Courtney D. DiNardo, MDMSc, Anthony S. Stein, MD, Amir T. Fathi, MD MD BS, Pau Montesinos, MD PhD, Olatoyosi Odenike, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Daniel O. Koralek, PhD, Jason Van Oostendorp, M.Sc., Jing Gong, PhD, Ira Gupta, MD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath

Blood (2017) 130 (Supplement 1): 639.

https://doi.org/10.1182/blood.V130.Suppl_1.639.639

Published: 2017

Journal Articles

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Eytan M. Stein, MD, Amir T. Fathi, MD, Courtney D DiNardo, MD, Daniel A Pollyea, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Gail J. Roboz, MD, Robert Collins, Mikkael A. Sekeres, MD, Richard M. Stone, MD, Eyal C Attar, Alessandra Tosolini, BS, Qiang Xu, PhD, Michael Amatangelo, PhD, Ira Gupta, MD, Robert D. Knight, MD, Stéphane De Botton, MD PhD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 343.

https://doi.org/10.1182/blood.V128.22.343.343

Published: 2016

Journal Articles

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Anders Österborg, Miklós Udvardy, Andrey Zaritskey, Per-Ola Andersson, Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, Grygoriy Rekhtman, Michele Gorczyca, Siobhan Daly, Chang Chai-Ni, Steen Lisby, Ira Gupta

Blood (2014) 124 (21): 4684.

https://doi.org/10.1182/blood.V124.21.4684.4684

Published: 2014

NARROW

Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2 ) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time

Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML)

Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only